🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
530,76 USD
Máx. histórico
558,88
4 días
Split 2:1 del 24/08/2000
Caída desde máximo
-5,03%
Rango 52 semanas
403,16 – 568,67
Variación hoy
-4,05%
Cierre anterior
553,15
Rango de hoy
529,15 – 561,96
Volumen hoy
2.372.462
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 30,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 576,29 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 07/05/1993 | 4,25 | 4,88 | 4,00 | 4,50 | +12,50% | 20,59% | 301.800 |
| 06/05/1993 | 3,88 | 4,25 | 3,88 | 4,00 | -1,54% | 9,68% | 205.600 |
| 05/05/1993 | 4,06 | 4,25 | 3,88 | 4,06 | -4,41% | 9,23% | 454.000 |
| 04/05/1993 | 4,25 | 4,25 | 3,88 | 4,25 | +9,68% | 8,82% | 38.400 |
| 03/05/1993 | 4,25 | 4,25 | 3,88 | 3,88 | -6,06% | 8,82% | 1.800 |
| 30/04/1993 | 3,88 | 4,13 | 3,88 | 4,13 | +0,00% | 6,45% | 5.400 |
| 29/04/1993 | 4,13 | 4,13 | 4,00 | 4,13 | +1,54% | 3,03% | 800 |
| 28/04/1993 | 4,00 | 4,13 | 3,75 | 4,06 | +4,84% | 9,38% | 58.000 |
| 27/04/1993 | 4,00 | 4,00 | 3,75 | 3,88 | -1,59% | 6,25% | 4.400 |
| 26/04/1993 | 3,88 | 4,13 | 3,75 | 3,94 | +0,00% | 9,68% | 50.800 |
| 23/04/1993 | 3,88 | 4,13 | 3,88 | 3,94 | -4,55% | 6,45% | 239.400 |
| 22/04/1993 | 3,88 | 4,13 | 3,88 | 4,13 | +1,54% | 6,45% | 5.800 |
| 21/04/1993 | 4,13 | 4,13 | 3,88 | 4,06 | +1,56% | 6,06% | 12.400 |
| 20/04/1993 | 4,00 | 4,25 | 3,94 | 4,00 | +0,00% | 7,81% | 44.800 |
| 19/04/1993 | 3,88 | 4,13 | 3,88 | 4,00 | +3,23% | 6,45% | 128.400 |
| 16/04/1993 | 4,13 | 4,13 | 3,88 | 3,88 | -3,13% | 6,06% | 14.000 |
| 15/04/1993 | 4,13 | 4,13 | 3,88 | 4,00 | +3,23% | 6,06% | 8.600 |
| 14/04/1993 | 4,25 | 4,25 | 3,88 | 3,88 | -4,62% | 8,82% | 77.000 |
| 13/04/1993 | 4,00 | 4,25 | 4,00 | 4,06 | +4,84% | 6,25% | 25.800 |
| 12/04/1993 | 4,00 | 4,13 | 3,88 | 3,88 | +0,00% | 6,25% | 39.200 |
| 08/04/1993 | 3,75 | 4,00 | 3,75 | 3,88 | +3,33% | 6,67% | 16.400 |
| 07/04/1993 | 3,88 | 4,00 | 3,75 | 3,75 | +0,00% | 6,45% | 20.200 |
| 06/04/1993 | 3,75 | 3,88 | 3,75 | 3,75 | +0,00% | 3,33% | 18.800 |
| 05/04/1993 | 4,00 | 4,00 | 3,75 | 3,75 | +0,00% | 6,25% | 10.800 |
| 02/04/1993 | 3,88 | 4,00 | 3,75 | 3,75 | +0,00% | 6,45% | 23.200 |
| 01/04/1993 | 4,00 | 4,00 | 3,75 | 3,75 | -6,25% | 6,25% | 41.600 |
| 31/03/1993 | 3,75 | 4,00 | 3,75 | 4,00 | +4,92% | 6,67% | 17.000 |
| 30/03/1993 | 4,13 | 4,13 | 3,75 | 3,81 | -1,61% | 9,09% | 284.400 |
| 29/03/1993 | 4,13 | 4,13 | 3,75 | 3,88 | -6,06% | 9,09% | 35.800 |
| 26/03/1993 | 4,13 | 4,13 | 3,75 | 4,13 | +0,00% | 9,09% | 29.800 |